ARTICLE | Finance
Performance Counts
Europe's best-performing biotechs took on more risk, raised the most money
May 31, 2010 7:00 AM UTC
BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond.
While in total these private and public biotechs also have registered the largest amount of money needed to finance the next three years of runway - €3.5 billion ($4.8 billion) - the individual companies are showing a continued trend toward burning less money to advance their programs...